Health Catalyst's third quarter carried a flattering GAAP headline, but the underlying result was weaker. The company reported an adjusted loss of $0.03 per share, missing the -$0.02 consensus by 400.0% and falling well short of the $0.01 Earnings Whisper number. Adjusted earnings fell 150.0% from a year ago. Revenue of $56.28 million beat the $55.19 million consensus by 2.0% but fell 26.3% year over year. GAAP net income of $40.5 million, or $0.53 per diluted share, compared with a $22.2 million loss a year earlier. That swing came almost entirely from a $65.9 million gain on the Vitalware sale, partly offset by a $9.5 million loss on extinguishment of debt. Strip out the transaction accounting and the central tension is plain: the balance sheet was repaired, but the remaining business is smaller, less profitable and still losing clients.

The quality of the beat deserves scrutiny. Revenue and adjusted EBITDA did land above the high end of guidance. Adjusted EBITDA was $779,000 against a $0 to $0.5 million range. But that range was a very low bar, and EBITDA fell from $12.0 million a year ago and $9.9 million in the second quarter. Adjusted gross margin dropped to 44% from 53% a year earlier and 51% in Q2. Technology adjusted gross margin slipped to 61% from 68%. Professional services collapsed to a 2% adjusted gross margin from 19% and posted a negative GAAP gross margin. Adjusted operating expenses rose to 43% of revenue from 37%. Retention investments for staff partly offset the Project Nexus savings, which management said are tracking plan. Excess internal medical-claims costs of roughly $1.6 million added to the pressure.

The revenue trajectory explains why investors should not read this as a trough. Quarterly revenue moved from $74.7 million in Q4 2025 to $70.8 million, $70.5 million and now $56.3 million. Q3 still included one month of Vitalware, so Q4 will be the first clean quarter without it. Full-year guidance of $246 million to $249 million in revenue and $18 million to $18.5 million in adjusted EBITDA was reaffirmed. Those ranges were already cut sharply in Q2, from $260 million to $265 million and from $30 million to $33 million. Reaffirming them now implies an adjusted EBITDA loss in the fourth quarter, roughly $3 million by the call's framing. The underlying churn problem has not improved:

• the $12.5 million notified-churn figure is unchanged;
• the $30 million at-risk ARR framework is unchanged;
• attrition tied to the migration from DOS to Ignite is expected to continue through the end of 2027;
• management will deliberately exit an unprofitable HIE interoperability relationship at the end of 2026, adding another revenue headwind.

There are genuine positives. Bookings are now expected to exceed the high end of the $22 million to $26 million full-year target, the only operating metric that was raised. Health Catalyst is now debt-free, with about $79 million in cash and short-term investments, versus more than $150 million of term debt at year-end. Nine-month operating cash flow swung to a positive $16.9 million from a $9.2 million outflow. New CEO Simeon Kohl, who joined in mid-September, framed his priorities as client retention, cost alignment, simplification and execution, and promised new investor KPIs. That is a credible restructuring agenda. It is not a growth story, and Kohl is the company's second CEO change this year, with key strategic decisions still pending. Bears also have legitimate ammunition in the fact that no analysts asked questions on the call, a sign of thin engagement.

The market setup is more complicated than the revenue beat implies. Investor sentiment swung sharply into the report, from -0.26 after the August release to +0.65. That shift helps explain a whisper number above consensus, a bar the company missed. Price action has been far less enthusiastic. Shares sat at $1.59, down 14.5% since the open following the prior report and 6.6% below the 200-day moving average of $1.70. The stock was 15.9% off its September 22 inter-earnings high of $1.89 and just 10.8% above the $1.44 low set on November 3. The Earnings Whispers trend signals are mostly negative, with sequential growth, momentum and AVWAP all deteriorating.

The bottom line is that Health Catalyst used the Vitalware sale to buy time and balance-sheet flexibility, and the bookings upgrade offers an early sign of commercial stabilization. But this quarter exposed margins and churn in the remaining business that do not yet support durable profitability. Investors should watch whether Q4 margins stabilize, whether the at-risk ARR figure finally shrinks and what the new KPIs reveal.